Cost-effectiveness of partial reimbursement for hepatitis B anti-viral drugs in Beijing, China: an analysis based on a retrospective cohort study

被引：0
|
作者：
Qiu, Qian [1 ]
Li, Yan [2 ]
Cheng, Kai-liang [1 ]
Duan, Xiao-wan [2 ]
Li, Hui [1 ]
Yang, Li-kun [2 ]
Duan, Zhong-ping [2 ]
Wang, Li [1 ]
机构：
[1] Peking Union Med Coll, Chinese Acad Med Sci, Dept Epidemiol & Biostat, Beijing 100005, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Ctr Liver, Beijing 100069, Peoples R China
来源：
LANCET | 2015年 / 386卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey
    Kockaya, Guvenc
    Kose, Akin
    Yenilmez, Fatma Betul
    Ozdemir, Oktay
    Kucuksayrac, Ece
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2015, 13
  • [2] Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey
    Guvenc Kockaya
    Akin Kose
    Fatma Betul Yenilmez
    Oktay Ozdemir
    Ece Kucuksayrac
    [J]. Cost Effectiveness and Resource Allocation, 13
  • [3] Cost-effectiveness analysis of anti-viral treatments in patients with chronic hepatitis B infection in Hong Kong
    Lam, T. P. Elegance
    Lam, Cindy L. K.
    Lai, C. L.
    Yuen, M. F.
    McGhee, Sarah
    Fong, Daniel
    Leung, Gabriel
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 : 61 - 61
  • [4] ANTI-VIRAL TREATMENT OF CHRONIC HEPATITIS C IN A PAEDIATRIC POPULATION: A COST-EFFECTIVENESS ANALYSIS
    Mernagh, P.
    Norris, S.
    Del Cuore, M.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A403 - A403
  • [5] Cost-effectiveness of growth factors during hepatitis C anti-viral therapy
    Chapko, M. K.
    Dominitz, J. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (07) : 1067 - 1077
  • [6] THE COST EFFECTIVENESS ANALYSIS OF THE ORAL ANTI-VIRAL TREATMENTS ALTERNATIVES FOR THE CHRONIC HEPATITIS B IN TURKEY
    Kockaya, G.
    Kose, A.
    Dalgic, C.
    Yenilmez, F. B.
    Ozdemir, O.
    Kucuksayrac, E.
    Tayfun, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [7] Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis
    Veenstra, D. L.
    Spackman, D. E.
    Bisceglie, A.
    Kowdley, K. V.
    Gish, R. G.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (12) : 1240 - 1252
  • [8] Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
    Yakubu, I.
    Zhang, Y.
    Ijioma, S.
    Carroll, N. V.
    Patterson, J.
    Sterling, R.
    Gupta, G.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 483 - 483
  • [9] Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis
    Wu, Bin
    Li, Te
    Chen, Huafeng
    Shen, Jinfang
    [J]. VALUE IN HEALTH, 2010, 13 (05) : 592 - 600
  • [10] Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis (vol 27, pg 1240, 2008)
    Di Bisceglie, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) : 166 - 166
12345